A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) - Catalog

Name

A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)

Accession Number

HLB00300404a

Acronym

ACCESS

Related studies

BSI Study IDs

ACC

Is public use dataset

False

Keywords

Has Study Datasets

True

Has Specimens

True

Specimen ID Type

Coded

Study Website

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Study type

Epidemiology Study

Collection Type

Open BioLINCC Study

Cohort type

Adult

Interventions

Study Open Date (Data)

2009-10-01

Study Open Date (Specimens)

2009-10-01

Date materials available

2008-10-01

Last updated

2005-12-21

Study period

June 1995 - March 2003

Study Contacts
NHLBI Division

DLD

Classification

Lung

HIV study classification

non-HIV

COVID study classification

non-COVID

Pre-Website # of Specimens Shipped

11211

# of Returned Specimens

0

Primary Publication URLs
N/A
Conditions

Lung Diseases
Sarcoidosis

Objectives

To determine the etiology of sarcoidosis by establishing a case control, multi-center study. In addition to etiology, this study also sought to examine socioeconomic variables and the clinical course of patients with sarcoidosis, including quality of life.

Background

Sarcoidosis is a chronic granulomatous disorder of unknown cause that is characterized by activation of T-lymphocytes and macrophages. For many years sarcoidosis was presumed to be an atypical manifestation of tuberculosis because of the similarity between the inflammatory responses of the two diseases. However, as culture techniques became more widely employed to diagnose tuberculosis and it became less common, it became clear that sarcoidosis was not simply a variation of tuberculosis. Data on the etiology of sarcoidosis have come from diverse sources: in clinical investigations, alveolitis has been found to precede granulomatous inflammation; in case control studies, familial aggregation has been identified; and in case reports, recurrence of granulomatous inflammation has been observed after lung transplantation. The cause may not prove to be a single, known exposure. Interactions of exposures with genetic dispositions could have important implications for our understanding of immune responses as well as the pathogenesis of sarcoidosis.

Participants

736 patients with sarcoidosis enrolled within 6 months of diagnosis from 10 clinical centers in the U.S. Using the ACCESS sarcoidosis assessment system, organ involvement was determined for the whole group and for subgroups differentiated by sex, race, and age (<40 or 40 and older). Cases were matched with a control, and there was a two-year follow-up on cases. The ACCESS group proposed an instrument fo defining organ involvement in sarcoidosis. Biological specimens included DNA, plasma, and bronchoalveolar lavage samples were obtained. The data set includes 718 cases, 686 controls, and two-year follow-up data on 241 cases.

Design

Conclusions

The initial presentation of sarcoidosis is related to sex, race and age, and it tends to remain stable over two years in the majority of patients. The etiology is probably multifactoral with both genetic and environmental factors contributing.

Disease classification

Publications

Mat types

Bronchial Lavage
DNA
Peripheral Blood Mononuclear Cells
Plasma

Network

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    Cases: 718

    Controls: 686


    Last Modified: July 1, 2024, 2:30 p.m.
  • Age

     

    Case

    Control

    Total Subjects

    18-29

    80

    75

    155

    30-39

    247

    222

    469

    40-49

    214

    224

    438

    50-59

    129

    118

    247

    >=60

    48

    47

    95


    Last Modified: July 1, 2024, 2:30 p.m.
  • Sex

     

    Case

    Control

    Total Subjects

    Male

    261

    243

    504

    Female

    457

    443

    900


    Last Modified: July 1, 2024, 2:30 p.m.
  • Race

     

    Case

    Control

    Total Subjects

    White

    393

    380

    773

    Black or African American

    325

    306

    631


    Last Modified: July 1, 2024, 2:30 p.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types

    Last Modified: Nov. 30, 2015, 10:16 a.m.
  • General Freeze/Thaw Status
  • Visits (Vials)

    10/31/2024

    Plasma

    DNA

    PBMC

    Bronchoalveolar Lavage (BAL)

    Total Vials

    14,488

    29,389

    1,394

    633

    45,904


    Last Modified: Oct. 31, 2024, 9:24 a.m.
  • Visits (Subjects)

    10/31/2024

    Plasma

    Total number of subjects

    Average volume (mL) per subject

    1,424

    11.87

     

    DNA

    Total number of subjects

    Average mass (mg) per subject

    1,426

    20.61

     

    PBMC

    Total number of subjects

    Average volume (mL) per subject

    1,218

    1.14

     

    Bronchoalveolar Lavage (BAL)

    Total number of subjects

    Average volume (mL) per subject

    73

    8.67


    Last Modified: Oct. 31, 2024, 9:24 a.m.